Prices are closing data as of 2026-11-04, not real-time quotes. HK P/E and P/B multiples come from Eastmoney HK key statistics. Metric definitions: P/E, P/B, ROE.
Want the full AI research report for GIANT BIOGENE?
This free page compiles public filings, financial ratios and risk screening. Generate a full research report to add business moat & competition, valuation scenarios, catalysts and bull/bear cases right at this URL.
New users who sign up free and verify their email receive 2 free credits for research reports or professional valuation.
10-Year FinancialsFY2019–2025
Financial statements are reported in CNY, while share price and market cap are quoted in HKD.
Key Multi-Year Facts
- Revenue moved from CN¥956.7M in FY2019 to CN¥5.52B in FY2025 (6-year CAGR +33.9%).
- Profitable in every fiscal year across 2019–2025.
Latest 5 Fiscal Years
| Fiscal Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue (CNY B) | 1.55 | 2.36 | 3.52 | 5.54 | 5.52 |
| YoY | 30.4% | 52.3% | 49.0% | 57.2% | -0.4% |
| Net Income (CNY B) | 0.83 | 1.00 | 1.45 | 2.06 | 1.91 |
| YoY | 0.2% | 21.0% | 44.9% | 42.1% | -7.2% |
| Operating Cash Flow (CNY B) | 0.69 | 0.93 | 1.65 | 2.04 | 1.78 |
| ROE | 112.3% | 52.0% | 40.4% | 36.0% | 22.5% |
| Gross Margin | 87.2% | 84.4% | 83.6% | 82.1% | 80.3% |
| Net Margin | 53.3% | 42.4% | 41.2% | 37.2% | 34.7% |
| Debt-to-Assets | 87.1% | 9.6% | 12.1% | 11.4% | 8.5% |
Show all 7 fiscal years
| Fiscal Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue (CNY B) | 0.96 | 1.19 | 1.55 | 2.36 | 3.52 | 5.54 | 5.52 |
| YoY | — | 24.4% | 30.4% | 52.3% | 49.0% | 57.2% | -0.4% |
| Net Income (CNY B) | 0.55 | 0.83 | 0.83 | 1.00 | 1.45 | 2.06 | 1.91 |
| YoY | — | 49.6% | 0.2% | 21.0% | 44.9% | 42.1% | -7.2% |
| Operating Cash Flow (CNY B) | 0.66 | 0.83 | 0.69 | 0.93 | 1.65 | 2.04 | 1.78 |
| ROE | 48.1% | 102.9% | 112.3% | 52.0% | 40.4% | 36.0% | 22.5% |
| Gross Margin | 83.3% | 84.6% | 87.2% | 84.4% | 83.6% | 82.1% | 80.3% |
| Net Margin | 57.7% | 69.4% | 53.3% | 42.4% | 41.2% | 37.2% | 34.7% |
| Debt-to-Assets | 35.9% | 82.7% | 87.1% | 9.6% | 12.1% | 11.4% | 8.5% |
Fiscal years follow the period-end calendar year (hover headers for period-end dates). ROE uses average beginning/ending equity. Source: HKEX / Eastmoney financial statements, compiled mechanically without AI. Official filings
Risk ChecklistAs of 2026-11-05
Rules-based screening using HK financial statements and HKEX announcement categories (no AI opinions).
Items Flagged for Review
-
Watch
Auditor ChangeMaterial Events
An "Alert" or "Watch" item flags a number that merits verification in primary filings, not a sell signal.
Dividends
Trailing 12-month dividend: HK$1.389 per share, or 6.81% yield at closing price; last full fiscal year: HK$1.389 (payout ratio 77.5%).
Figures are gross HKD per share before applicable withholding or Stock Connect dividend taxes.
More data: All research reports · Sector leaders · Market hours & holidays.
Compiled mechanically from public filings and market quotes (data as of 2026-11-05). For informational purposes only, not investment advice.